microRNA expression alteration after arsenic trioxide treatment in HepG-2 cells. 2011

Xian-Zhi Meng, and Tong-Sen Zheng, and Xi Chen, and Jia-Bei Wang, and Wei-Hui Zhang, and Shang-Ha Pan, and Hong-Chi Jiang, and Lian-Xin Liu
Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.

OBJECTIVE More and more microRNA (miRNA) are found to be involved in tumor genesis and progress. Arsenic trioxide has been an effective chemotherapeutic drug in cancer therapy for many years. In this study, we aimed to find the miRNA involved in the mechanisms of arsenic trioxide treatment in cancer therapy. METHODS We detected the expression profile of miRNA by miRNA microarray and quantitative real-time polymerase chain reaction. Cell viability assay, flow cytometry analysis, prediction of miRNA targets, Western blot analysis and luciferase reporter assay were carried out to determine the role of one selected miRNA, namely mir-29a, in affecting the biological behaviors of HepG-2 cells. RESULTS Among the 677 human miRNA in the microarray, five miRNA were upregulated and four were downregulated in HepG-2 cells treated with arsenic trioxide compared to their controls. If only changes above two folds were considered, four miRNA were identified, namely miR-24, miR-29a, miR-30a and miR-210, which were all upregulated. Among them, miR-29a showed a positive therapeutic effect in liver cancer cells by inhibiting cell growth and inducing cell apoptosis, and PPM1D was confirmed to be the target gene of miR-29a. Furthermore, a synergy effect was detected between miR-29a and arsenic trioxide. CONCLUSIONS Arsenic trioxide altered miRNA expression profile in HepG-2 cells. Among the altered miRNA, miR-29a seemed to take a role in the mechanism of arsenic trioxide in liver cancer therapy. The synergy effect between miR-29a and arsenic trioxide may offer this drug a new chance in cancer therapy by decreasing its dose and toxic side-effects.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D010087 Oxides Binary compounds of oxygen containing the anion O(2-). The anion combines with metals to form alkaline oxides and non-metals to form acidic oxides. Oxide
D010749 Phosphoprotein Phosphatases A group of enzymes removing the SERINE- or THREONINE-bound phosphate groups from a wide range of phosphoproteins, including a number of enzymes which have been phosphorylated under the action of a kinase. (Enzyme Nomenclature, 1992) Phosphoprotein Phosphatase,Phosphoprotein Phosphohydrolase,Protein Phosphatase,Protein Phosphatases,Casein Phosphatase,Ecto-Phosphoprotein Phosphatase,Nuclear Protein Phosphatase,Phosphohistone Phosphatase,Phosphoprotein Phosphatase-2C,Phosphoseryl-Protein Phosphatase,Protein Phosphatase C,Protein Phosphatase C-I,Protein Phosphatase C-II,Protein Phosphatase H-II,Protein-Serine-Threonine Phosphatase,Protein-Threonine Phosphatase,Serine-Threonine Phosphatase,Threonine Phosphatase,Ecto Phosphoprotein Phosphatase,Phosphatase C, Protein,Phosphatase C-I, Protein,Phosphatase C-II, Protein,Phosphatase H-II, Protein,Phosphatase, Casein,Phosphatase, Ecto-Phosphoprotein,Phosphatase, Nuclear Protein,Phosphatase, Phosphohistone,Phosphatase, Phosphoprotein,Phosphatase, Phosphoseryl-Protein,Phosphatase, Protein,Phosphatase, Protein-Serine-Threonine,Phosphatase, Protein-Threonine,Phosphatase, Serine-Threonine,Phosphatase, Threonine,Phosphatase-2C, Phosphoprotein,Phosphatases, Phosphoprotein,Phosphatases, Protein,Phosphohydrolase, Phosphoprotein,Phosphoprotein Phosphatase 2C,Phosphoseryl Protein Phosphatase,Protein Phosphatase C I,Protein Phosphatase C II,Protein Phosphatase H II,Protein Phosphatase, Nuclear,Protein Serine Threonine Phosphatase,Protein Threonine Phosphatase,Serine Threonine Phosphatase
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071636 Protein Phosphatase 2C One of four major classes of mammalian serine/threonine specific protein phosphatases. Protein phosphatase 2C is a monomeric enzyme about 42 kDa in size. It shows broad substrate specificity dependent on divalent cations (mainly manganese and magnesium). Three isozymes are known in mammals: PP2C -alpha, -beta and -gamma. In yeast, there are four PP2C homologues: phosphatase PTC1 that have weak tyrosine phosphatase activity, phosphatase PTC2, phosphatase PTC3, and PTC4. Isozymes of PP2C also occur in Arabidopsis thaliana where the kinase-associated protein phosphatase (KAPP) containing a C-terminal PP2C domain, dephosphorylates Ser/Thr receptor-like kinase RLK5. Magnesium-Dependent Protein Phosphatase 2C beta,PP2C beta,PP2Cepsilon,PP2Cgamma,PPM1 Magnesium-Dependent Protein Phosphatases,PPM1 Protein Phosphatases,PPM1D Phosphatase,PPM1E Phosphatase,PPM1G Phosphatase,Ppm1b Phosphatase,Protein Phosphatase 1D Magnesium-Dependent, delta isoform,Protein Phosphatase 2C beta,Protein Phosphatase 2C delta,Protein Phosphatase 2C epsilon,Protein Phosphatase 2C gamma,Ptc2 Phosphatase,2C, Protein Phosphatase,Magnesium Dependent Protein Phosphatase 2C beta,PPM1 Magnesium Dependent Protein Phosphatases,Phosphatase 2C, Protein,Phosphatase, PPM1D,Phosphatase, PPM1E,Phosphatase, PPM1G,Phosphatase, Ppm1b,Phosphatase, Ptc2,Phosphatases, PPM1 Protein,Protein Phosphatase 1D Magnesium Dependent, delta isoform,Protein Phosphatases, PPM1,beta, PP2C
D000077237 Arsenic Trioxide An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy. Arsenic Oxide (As2O3),Arsenic Oxide (As4O6),Arsenic(III) Oxide,Arsenolite,Arsenous Anhydride,As2O3,As4O6,Diarsenic Trioxide,Naonobin,Tetra-Arsenic Hexaoxide,Tetra-Arsenic Oxide,Tetraarsenic Hexaoxide,Tetraarsenic Oxide,Trisenox,Trixenox,Tetra Arsenic Hexaoxide,Tetra Arsenic Oxide

Related Publications

Xian-Zhi Meng, and Tong-Sen Zheng, and Xi Chen, and Jia-Bei Wang, and Wei-Hui Zhang, and Shang-Ha Pan, and Hong-Chi Jiang, and Lian-Xin Liu
January 2008, Metal ions in biology and medicine : proceedings of the ... International Symposium on Metal Ions in Biology and Medicine held ... = Les ions metalliques en biologie et en medecine : ... Symposium international sur les ions metalliques ...,
Xian-Zhi Meng, and Tong-Sen Zheng, and Xi Chen, and Jia-Bei Wang, and Wei-Hui Zhang, and Shang-Ha Pan, and Hong-Chi Jiang, and Lian-Xin Liu
January 2001, Anticancer research,
Xian-Zhi Meng, and Tong-Sen Zheng, and Xi Chen, and Jia-Bei Wang, and Wei-Hui Zhang, and Shang-Ha Pan, and Hong-Chi Jiang, and Lian-Xin Liu
April 2005, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Xian-Zhi Meng, and Tong-Sen Zheng, and Xi Chen, and Jia-Bei Wang, and Wei-Hui Zhang, and Shang-Ha Pan, and Hong-Chi Jiang, and Lian-Xin Liu
January 2013, Neoplasma,
Xian-Zhi Meng, and Tong-Sen Zheng, and Xi Chen, and Jia-Bei Wang, and Wei-Hui Zhang, and Shang-Ha Pan, and Hong-Chi Jiang, and Lian-Xin Liu
January 2015, Anti-cancer agents in medicinal chemistry,
Xian-Zhi Meng, and Tong-Sen Zheng, and Xi Chen, and Jia-Bei Wang, and Wei-Hui Zhang, and Shang-Ha Pan, and Hong-Chi Jiang, and Lian-Xin Liu
February 2011, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Xian-Zhi Meng, and Tong-Sen Zheng, and Xi Chen, and Jia-Bei Wang, and Wei-Hui Zhang, and Shang-Ha Pan, and Hong-Chi Jiang, and Lian-Xin Liu
June 2007, International journal of hematology,
Xian-Zhi Meng, and Tong-Sen Zheng, and Xi Chen, and Jia-Bei Wang, and Wei-Hui Zhang, and Shang-Ha Pan, and Hong-Chi Jiang, and Lian-Xin Liu
December 2015, Postepy higieny i medycyny doswiadczalnej (Online),
Xian-Zhi Meng, and Tong-Sen Zheng, and Xi Chen, and Jia-Bei Wang, and Wei-Hui Zhang, and Shang-Ha Pan, and Hong-Chi Jiang, and Lian-Xin Liu
January 2007, Molecular cancer therapeutics,
Xian-Zhi Meng, and Tong-Sen Zheng, and Xi Chen, and Jia-Bei Wang, and Wei-Hui Zhang, and Shang-Ha Pan, and Hong-Chi Jiang, and Lian-Xin Liu
July 2010, Chinese medical journal,
Copied contents to your clipboard!